FATE Q2 2019 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+174.3% YoY

Gross Profit

-$19M-667.9% margin

Operating Income

-$24M-855.0% margin

Net Income

-$23M-833.4% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+7.0%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$22M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$200M

Total Liabilities

$72M

Stockholders' Equity

$128M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+174.3%
Gross Profit	-$19M	-$16M	-19.2%
Operating Income	-$24M	-$20M	-22.8%
Net Income	-$23M	-$20M	-19.5%